Sp946
EVALUATION OF GASTROPARESIS
Date
May 20, 2024
Presenter
Temple Univ School of Medicine
Tracks
Related Products
SPECIFIC PATIENT PHENOTYPING IN GASTRODUODENAL DISORDERS USING GASTRIC ALIMETRY® WITH COMPARISON TO GASTRIC EMPTYING SCINTIGRAPHY
INTRODUCTION: Patients with upper gastrointestinal (UGI) symptoms of abdominal pain, nausea, vomiting, and bloating often complain within the postprandial period…
SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL
BACKGROUND: Survodutide is a novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist under investigation for treatment in advanced liver disease associated with metabolic dysfunction-associated steatohepatitis (MASH), the most severe form of metabolic dysfunction-associated steatotic…
IS IT DYSPEPSIA OR GASTROPARESIS
Back by popular demand, the experts will share and debate the evidence and their approaches to chronic pain, defecatory disorders, dyspepsia. and gastroparesis…
